Sugi Predict

Sugi Predict / Compounds / SCHEMBL406865

SCHEMBL406865

SCHEMBL406865

COC(=O)c1ccc(C(N)=NO)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ GAA P10253 3/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ RECQL P46063 1/20 0.45
▸ KMT2A Q03164 1/20 0.44
▸ CFTR P13569 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL406864 1.00 KDM4E (0.47) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL8401255 1.00 KDM4E (0.47) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL2773595 0.90 SMN1; SMN2 (0.41) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL2776991 0.88 KDM4E (0.51) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL9968900 0.88 RECQL (0.45) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL2777533 0.88 RECQL (0.45) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL9968898 0.88 KDM4E (0.51) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL2776989 0.88 KDM4E (0.51) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL2777532 0.88 RECQL (0.45) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL6116186 0.84 GAA (0.50) KDM4EALDH1A1GAAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233842-B1 BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARB) AGONISTS KING S COLLEGE LONDON (GB) 2025-03-26 — — EP disclosed
US-11401265-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists KING'S COLLEGE LONDON 2022-08-02 — — US disclosed
CN-107207488-B Bicyclic heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RAR) agonists 伦敦皇家学院 2020-11-17 — — CN disclosed
US-10385044-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists KING'S COLLEGE LONDON (GB) 2019-08-20 — — US disclosed
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 — — EP disclosed
US-9994559-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists KING'S COLLEGE LONDON (GB) 2018-06-12 — — US disclosed
US-20170327489-A1 Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists KING'S COLLEGE LONDON (GB) 2017-11-16 — — US disclosed
EP-2414341-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-09-13 — — EP disclosed
US-9725438-B2 Substituted phenylazole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-08-08 — — US disclosed
EP-3009433-B1 2-PHENYL-1,3-OXAZOLE AND 5-PHENYL-1,2,4-OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF DIABETES DAIICHI SANKYO CO LTD (JP) 2017-06-21 — — EP disclosed
EP-2414341-A2 OXADIAZOLE DERIVATIVES Merck Serono SA (CH) 2012-02-08 — — EP disclosed
US-20120022109-A1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2012-01-26 — — US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 — — US disclosed
EP-2250165-A1 TRIAZOLE OXADIAZOLES DERIVATIVES Merck Serono S.A. (CH) 2010-11-17 — — EP disclosed
WO-2010115751-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-14 — — WO disclosed
WO-2010112461-A1 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2010-10-07 — — WO disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 — — US disclosed
EP-2193125-A2 OXADIAZOLE DERIVATIVES Merck Serono S.A. (CH) 2010-06-09 — — EP disclosed
WO-2009080663-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO S.A. (CH) 2009-07-02 — — WO disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401265-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists RARB, RARA, RXRB KDM4E 3621/4885ALDH1A1 238/4885GAA 2862/4885
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES OXA1L, RO60, PDCD11 KDM4E 1353/4885ALDH1A1 466/4885GAA 4078/4885
US-20170327489-A1 Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists RARB, RARA, RXRB KDM4E 3575/4885ALDH1A1 253/4885GAA 2906/4885
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 KDM4E 815/4885ALDH1A1 516/4885GAA 3886/4885
US-10385044-B2 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists RARB, RARA, RARG KDM4E 3651/4885ALDH1A1 239/4885GAA 2964/4885
US-20120022109-A1 OXADIAZOLE DERIVATIVES OXA1L, HLA-DRB1, SSB KDM4E 1908/4885ALDH1A1 510/4885GAA 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.